alanine has been researched along with imatinib mesylate in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bartella, V; Bussolari, R; Calabretta, B; Candini, O; Cesi, V; Corradini, F; Pani, E | 1 |
| Boshoff, C; Frow, R; Gana-Weisz, M; Hartzoulakis, B; McLean, SR; Selwood, D; Whelan, J | 1 |
| Lagonigro, MS; Miselli, F; Negri, T; Pilotti, S; Pricl, S; Tamborini, E | 1 |
| Daeyaert, F; De Jonge, M; Koymans, L; Vinkers, M | 1 |
| Dubey, KD; Ojha, RP | 1 |
| Alshaeri, HK; Natto, ZS | 1 |
1 review(s) available for alanine and imatinib mesylate
| Article | Year |
|---|---|
A contemporary look at COVID-19 medications: available and potentially effective drugs.
Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Imatinib Mesylate; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
5 other study(ies) available for alanine and imatinib mesylate
| Article | Year |
|---|---|
Enhanced proliferative potential of hematopoietic cells expressing degradation-resistant c-Myb mutants.
Topics: Alanine; Animals; Apoptosis; Benzamides; Blotting, Northern; Blotting, Western; Cell Cycle; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Genes, Dominant; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Interleukin-3; K562 Cells; Leucine; Lithium Chloride; Lysine; Mice; Mice, Inbred C57BL; Mutation; Phosphatidylinositol 3-Kinases; Piperazines; Plasmids; Protein Structure, Tertiary; Proto-Oncogene Proteins c-myb; Pyrimidines; Retroviridae; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Time Factors; Transcription, Genetic; Transfection; Ubiquitin | 2005 |
Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala.
Topics: Alanine; Alleles; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Benzamides; Cell Line; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Models, Molecular; Molecular Sequence Data; Mutation, Missense; Piperazines; Pyrimidines; Sequence Homology, Amino Acid; Stem Cell Factor; Valine | 2005 |
Re: Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis.
Topics: Alanine; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Cysteine; Fibroma; Humans; Imatinib Mesylate; Leucine; Methionine; Mutagenesis; Mutation; Piperazines; Polymorphism, Genetic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome | 2006 |
An ant algorithm for the conformational analysis of flexible molecules.
Topics: Alanine; Algorithms; Alkanes; Benzamides; Computer Simulation; Factor Analysis, Statistical; Imatinib Mesylate; Models, Chemical; Molecular Conformation; Oligopeptides; Pharmaceutical Preparations; Piperazines; Pyrimidines; Vitamin A | 2007 |
Conformational flexibility, binding energy, role of salt bridge and alanine-mutagenesis for c-Abl kinase complex.
Topics: Alanine; Benzamides; Binding Sites; Glutamic Acid; Humans; Hydrogen Bonding; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Ligands; Lysine; Molecular Dynamics Simulation; Mutagenesis; Piperazines; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Salts; Thermodynamics | 2012 |